We participated in INS-IM 2022, a Neuromodulation conference at the Grand Hyatt Mumbai from November 11 to 13, 2022 in association with STORZ MEDICAL AG.
The Czech capital of Prague hosted the 24th edition of the ISMST World Congress (International Society for Medical Shockwave Treatment). Leading scientists and physicians from around the world presented the latest in research and practice in first-class lectures and workshops on all aspects of shock wave therapy.
Transcranial Pulse Stimulation (TPS) is a new non-invasive neuromodulation therapy that uses shockwaves for the treatment of Alzheimer ´ s Disease (AD). In humans, there is first evidence for beneficial clinical effects after a series of six TPS sessions. Long-term results and controlled trials are not yet reported. Experience from other centers is lacking. We report on first short-term and long-term clinical experience from a center in Germany with additional EEG recordings.
Ultrasound-based brain stimulation techniques may become a powerful new technique to modulate the human brain in a focal and targeted manner. However, for clinical brain stimulation no certified systems exist and the current techniques have to be further developed. Here, a clinical sonication technique is introduced, based on single ultrashort ultrasound pulses (transcranial pulse stimulation, TPS) which markedly differs from existing focused ultrasound techniques.In addition, a first clinical study using ultrasound brain stimulation and first observations of long term effects are presented. Comprehensive feasibility, safety, and efficacy data are provided.
Alzheimer’s disease (AD) is a very common cause of dementia in many countries all over the world and a common cause of death in elderly humans. No effective long-term treatment has been found yet. TPS (Transcranial Pulse Stimulation), which can be individually tracked by MRT-scans, offers new perspectives to ameliorate deficits caused by AD. Pilot studies show beneficial effects on learning and memory of TPS. There are also reports of restorative structural changes in the thickness of the cerebral cortex due to the stimulation.
Alzheimer's patients now also have access to Transcranial Pulse Stimulation (TPS) in Munich – one of the leading medical cities in Germany. In July 2021, a NEUROLITH system was installed in the private practice Schleicher & Brückl. It is the first NEUROLITH in the capital of Bavaria, the largest German state.
Transcranial Pulse Stimulation (TPS®) with the NEUROLITH® system for the treatment of Alzheimer's patients is increasingly gaining momentum: In early June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria and Turkey. In Germany, the Alexius/Josef Hospital in Neuss, with over 30 000 patients per year, opened a TPS® treatment centre under the direction of Prof. Dr Dr Dipl.-Psych. Ulrich Sprick (head physician of the outpatient services and day clinics). The respected specialist in psychiatry and psychotherapy is a lecturer at the Heinrich Heine University Düsseldorf and will work closely with STORZ MEDICAL in the future to further develop TPS®.
In early May 2021, two more NEUROLITH systems were installed in Germany. Both the renowned Klinikum Wahrendorff in Sehnde near Hanover and the private practice of Prof. Dr Musa Citak in Hamburg are expanding their range of therapies with Transcranial Pulse Stimulation (TPS).
There are various forms of brain stimulation, that are used in neurodegenerative disease. In this webinar neurologist Dr Lars Wojtecki talks about scientific background and clinical data of Transcranial Pulse Stimulation as well as practical experience with handling and clinical effects. Which patient to choose? How does TPS compare to TMS?
Prof. Dr Roland Beisteiner from Medical University Vienna delves into the latest science on Transcranial Pulse Stimulation (TPS) with NEUROLITH® system, the research behind it, his work and the success to date. This new technique allows unprecedented focal neuronal tissue stimulation reaching depths of as much as 8 cm in the brain and reflects an unparalleled advancement in the field of transcranial stimulation.
Transcranial Pulse Stimulation (TPS®) for the treatment of Alzheimer's patients is now also available for patients in Switzerland. In early February 2021, the first NEUROLITH® system was successfully installed in the Praxis Alexander Russ in Zurich.
Recording of session »Brain Stimulation with Shockwaves (TPS) for Alzheimer’s Disease Treatment« by Dr Pavel Novak Due to the high demand at Dementia 2021 virtual meeting Dr Pavel Novak has agreed to offer his lecture on the topic »Brain Stimulation with Shockwaves (TPS) for Alzheimer’s Disease Treatment« for STORZ MEDICAL partners.
Alzheimer's patients now also have access to Transcranial Pulse Stimulation (TPS) in Munich – one of the leading medical cities in Germany. In July 2021, a NEUROLITH system was installed in the private practice Schleicher & Brückl. It is the first NEUROLITH in the capital of Bavaria, the largest German state.
Transcranial Pulse Stimulation (TPS®) with the NEUROLITH® system for the treatment of Alzheimer's patients is increasingly gaining momentum: In early June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria and Turkey. In Germany, the Alexius/Josef Hospital in Neuss, with over 30 000 patients per year, opened a TPS® treatment centre under the direction of Prof. Dr Dr Dipl.-Psych. Ulrich Sprick (head physician of the outpatient services and day clinics). The respected specialist in psychiatry and psychotherapy is a lecturer at the Heinrich Heine University Düsseldorf and will work closely with STORZ MEDICAL in the future to further develop TPS®.
In early May 2021, two more NEUROLITH systems were installed in Germany. Both the renowned Klinikum Wahrendorff in Sehnde near Hanover and the private practice of Prof. Dr Musa Citak in Hamburg are expanding their range of therapies with Transcranial Pulse Stimulation (TPS).
There are various forms of brain stimulation, that are used in neurodegenerative disease. In this webinar neurologist Dr Lars Wojtecki talks about scientific background and clinical data of Transcranial Pulse Stimulation as well as practical experience with handling and clinical effects. Which patient to choose? How does TPS compare to TMS?
Transcranial Pulse Stimulation (TPS®) for the treatment of Alzheimer's patients is now also available for patients in Switzerland. In early February 2021, the first NEUROLITH® system was successfully installed in the Praxis Alexander Russ in Zurich.
Transcranial Pulse Stimulation (TPS®) for the treatment of Alzheimer's patients is now also available for patients in Switzerland. In early February 2021, the first NEUROLITH® system was successfully installed in the Praxis Alexander Russ in Zurich.
Watch the session »State of the Art of New Brain Stimulation Techniques« with Prof. Roland Beisteiner who presented on Transcranial Pulse Stimulation in patients with Alzheimer‘s disease on 12 November 2020.
We participated in INS-IM 2022, a Neuromodulation conference at the Grand Hyatt Mumbai from November 11 to 13, 2022 in association with STORZ MEDICAL AG.
The Czech capital of Prague hosted the 24th edition of the ISMST World Congress (International Society for Medical Shockwave Treatment). Leading scientists and physicians from around the world presented the latest in research and practice in first-class lectures and workshops on all aspects of shock wave therapy.
Transcranial Pulse Stimulation (TPS®) with the NEUROLITH® system for the treatment of Alzheimer's patients is increasingly gaining momentum: In early June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria and Turkey. In Germany, the Alexius/Josef Hospital in Neuss, with over 30 000 patients per year, opened a TPS® treatment centre under the direction of Prof. Dr Dr Dipl.-Psych. Ulrich Sprick (head physician of the outpatient services and day clinics). The respected specialist in psychiatry and psychotherapy is a lecturer at the Heinrich Heine University Düsseldorf and will work closely with STORZ MEDICAL in the future to further develop TPS®.
There are various forms of brain stimulation, that are used in neurodegenerative disease. In this webinar neurologist Dr Lars Wojtecki talks about scientific background and clinical data of Transcranial Pulse Stimulation as well as practical experience with handling and clinical effects. Which patient to choose? How does TPS compare to TMS?
Prof. Dr Roland Beisteiner from Medical University Vienna delves into the latest science on Transcranial Pulse Stimulation (TPS) with NEUROLITH® system, the research behind it, his work and the success to date. This new technique allows unprecedented focal neuronal tissue stimulation reaching depths of as much as 8 cm in the brain and reflects an unparalleled advancement in the field of transcranial stimulation.
Transcranial Pulse Stimulation (TPS) is a new non-invasive neuromodulation therapy that uses shockwaves for the treatment of Alzheimer ´ s Disease (AD). In humans, there is first evidence for beneficial clinical effects after a series of six TPS sessions. Long-term results and controlled trials are not yet reported. Experience from other centers is lacking. We report on first short-term and long-term clinical experience from a center in Germany with additional EEG recordings.
Ultrasound-based brain stimulation techniques may become a powerful new technique to modulate the human brain in a focal and targeted manner. However, for clinical brain stimulation no certified systems exist and the current techniques have to be further developed. Here, a clinical sonication technique is introduced, based on single ultrashort ultrasound pulses (transcranial pulse stimulation, TPS) which markedly differs from existing focused ultrasound techniques.In addition, a first clinical study using ultrasound brain stimulation and first observations of long term effects are presented. Comprehensive feasibility, safety, and efficacy data are provided.
Alzheimer’s disease (AD) is a very common cause of dementia in many countries all over the world and a common cause of death in elderly humans. No effective long-term treatment has been found yet. TPS (Transcranial Pulse Stimulation), which can be individually tracked by MRT-scans, offers new perspectives to ameliorate deficits caused by AD. Pilot studies show beneficial effects on learning and memory of TPS. There are also reports of restorative structural changes in the thickness of the cerebral cortex due to the stimulation.
The past 5 years have seen a surge in innovation and global productivity in FUS clinical efforts, with the demonstration of a favourable safety profile as well as versatility across and scalability within several clinical indications. Following regulatory approval of MRgFUS thalamotomy for ET and tremor-dominant PD, thermoablation has gone from experimental treatment to standard of care. Efficacy data for drug delivery via FUS BBBO are anticipated over the next 2 years, probably within the neuro-oncology field initially. Additionally, a growing number of registered trials are addressing the application of FUS neuromodulation in epilepsy, AD, PD, depression and traumatic brain injury.
Ultrasound‐based brain stimulation techniques may become a powerful new technique to modulate the human brain in a focal and targeted manner. However, for clinical brain stimulation no certified systems exist and the current techniques have to be further developed. Here, a clinical sonication technique is introduced, based on single ultrashort ultrasound pulses (transcranial pulse stimulation, TPS) which markedly differs from existing focused ultrasound techniques. In addition, a first clinical study using ultrasound brain stimulation and first observations of long term effects are presented.
We provide solutions for healthcare and research. We distribute medical equipment, provide scientific expertise and support to researcher
© 2020 Aerobe. All Rights Reserved Terms & Conditions | Privacy Policy